Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus glimepiride added to metformin in type 2 diabetes
IRCT20220408054450N1Phase 4Completed
- Sponsor
- Bahria University Medical & Dental College
- Start
- Oct 2019
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin, glimepiride and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bahria University Medical & Dental College. Primary endpoints: Hemoglobin A1c and Fasting plasma glucose. Started Oct 2019; status: completed.
02
Drugs
dapagliflozinglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20220408054450N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220408054450N1.